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Background: In patients with severe aortic stenosis, left ventricular hypertrophy is associated with increased
myocardial stiffness and dysfunction linked to cardiac morbidity and mortality. We aimed at systematically
investigating the degree of left ventricular mass regression and changes in left ventricular function six months after
transcatheter aortic valve implantation (TAVI) by cardiovascular magnetic resonance (CMR).
Methods: Left ventricular mass indexed to body surface area (LVMi), end diastolic volume indexed to body surface
area (LVEDVi), left ventricular ejection fraction (LVEF) and stroke volume (SV) were investigated by CMR before and
six months after TAVI in patients with severe aortic stenosis and contraindications for surgical aortic valve
replacement.
Results: Twenty-sevent patients had paired CMR at baseline and at 6-month follow-up (N=27), with a mean age of
80.7±5.2 years. LVMi decreased from 84.5±25.2 g/m2 at baseline to 69.4±18.4 g/m2 at six months follow-up
(P<0.001). LVEDVi (87.2±30.1 ml /m2vs 86.4±22.3 ml/m2; P=0.84), LVEF (61.5±14.5% vs 65.1±7.2%, P=0.08) and SV
(89.2±22 ml vs 94.7±26.5 ml; P=0.25) did not change significantly.
Conclusions: Based on CMR, significant left ventricular reverse remodeling occurs six months after TAVI.
Keywords: Ventricular remodeling, Transcatheter aortic valve implantation, Cardiovascular magnetic resonanceBackground
In patients with severe aortic stenosis, left ventricular
hypertrophy is a frequent pathophysiological adaptation
to pressure overload [1]. However, the enlarged myocardial
cell mass and interstitial fibrosis result in increased
myocardial stiffness and dysfunction [2-5]. Aortic valve
replacement reduces afterload in patients with severe
aortic stenosis. In recent years, transcatheter aortic valve
implantation (TAVI) has emerged as a valuable alternative
to surgical aortic valve replacement in patients at high
surgical risk because of age and/or comorbidities [6-10].
Numerous studies have shown excellent and sustained
transvalvular hemodynamics after TAVI, together with
a significant improvement in symptoms and quality of
life [11-13].* Correspondence: lamanna.cardio@gmail.com
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reproduction in any medium, provided the orHemodynamic changes that occur after TAVI have
been generally evaluated by echocardiographic methods
[14,15]. Cardiovascular magnetic resonance (CMR) is
more accurate and reproducible than two-dimensional
echocardiography in the three-dimensional volumetric
evaluation of left ventricular volumes, function and
mass [16]. However, there is a lack of knowledge on the
use of CMR in TAVI patients for assessing the above
parameters. To fill this gap, we aimed at using CMR to
investigate left ventricular reverse remodeling at six-month
after TAVI.Methods
Patients population
Twenty-seven patients who underwent successful TAVI
using the Medtronic CoreValve (Medtronic CoreValve
Percutaneous System, Medtronic CV) or Edwards SAPIEN
(Edwards Lifesciences Inc, Irvine, CA, USA) bioprosthesesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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six-month follow up (Figure 1). The institutional ethics
committee approved the study protocol and all patients
gave informed consent. All patients were informed
about the potential risks of CMR [17] and gave their
written consent. Inclusion and exclusion criteria were
previously reported [18].
Study endpoints
Left ventricular mass indexed to body surface area
(LVMi), left ventricular end diastolic volume indexed to
body surface area (LVEDVi), stroke volume (SV), left
ventricular ejection fraction (LVEF) and mass/volume
ratio were assessed at baseline and six months. The
occurrence of subendocardial fibrosis was assessed in
terms of late gadolinium enhancement (LGE) at baseline
and six months.
Cardiovascular magnetic resonance
All CMR studies were performed with a 1.5 Tesla
Magnetic Resonance Imaging scanner (Achieva, Philips
Medical Systems, Netherlands) with a flexible cardiac
five-element phased-array coil and a vector electrocar-
diogram for R wave triggering using a standard MRI
imaging protocol. In brief, multiple short axis (SAX)
cine images using a breath-hold steady state free precession
sequence with parallel imaging (balanced Fast Field
Echo (FFE); Repetition time (TR)/Echo time (TE) = 3.1/
1.56 ms; slice thickness 8 mm; matrix 180 x 175 ; flip
angle 60°; acquisition voxel-size = 1.78 × 1.82 × 8 mm3 ;
reconstructed voxel-size = 1.25 × 1.25 × 8 mm3 acquisition;
sensitivity encoding (SENSE)-factor = 2) were acquiredFigure 1 Study flow chart.after the acquisition of true two- and four- chamber
planes for the assessment of left ventricular ejection
fraction (LVEF %).The CMR images were analyzed
off-line using a commercial software (Philips Medical
Systems Extended MK Word Space Version 2.6.3.1)
by a blinded experienced CMR reader unaware of patients’
clinical data. For assessment of left ventricular function,
the end-diastolic and end-systolic cine frames were
identified for each slice and the endocardial and epicardial
borders were manually traced. The end-diastolic and
end-systolic volumes were then calculated using the
Simpson’s rule (i.e., sum of cavity sizes across all
continuous slices) and indexed to body surface area.
LVEF was calculated as (end-diastolic volume - end-
systolic volume)/end-diastolic volume. LVMi was derived
via the Simpson’s method multiplied by the specific gravity
of myocardium (1.055 g/ml) and indexed to the body
surface area. LVMi was divided by the LVEDVi to obtain
the mass/volume ratio. Normal values used in this study
for both LV systolic function and mass were those
reported by Maceira et al. [19]. Left ventricular reverse
remodeling was defined as a significant reduction in LVMi
between baseline and 6 months.
To evaluate LGE, an intravenous bolus dose of
0.2 mmol/kg body weight of gadobutrol (Gadovist, Bayer
Schering Pharma, Berlin, Germany) was administered at
a rate of 3 ml/s by a power injector (MedradSpectris
Solaris, Medrad, USA). Ten minutes after gadolinium
injection, a ‘Look Locker’ sequence was performed to
obtain the most appropriate inversion time to null the
signal intensity of normal myocardium. LGE images
were then acquired using the following parameters: fast
Table 1 Demographic and clinical characteristics
Variables N = 27
Male, n (%) 10 (37)
Age, (mean ± DS) 80.7 ± 5.2
Log EuroScore, (mean ± DS) 14.9 ± 12
BMI, (mean ± DS) 27.5 ± 5.5
Symptoms
Syncope, n (%) 4 (14.8)
Unstable Angina, n (%) 6 (22.3)
Hospitalization for heart failure, n (%) 10 (37)
Dyspnoea, n (%) 25 (92.6)
RiskFactors
Hypertension, n (%) 23 (85.1)
Diabetes , n (%) 4 (14.8)
Hypercholesterolemia, n (%) 9 (33.3)
Smoker, n (%) 3 (11.1)
Ex smoker, n (%) 2 (7.4)
Cirrhosis, n (%) 1 (3.7)
Renal failure (creatinine > 2 mg/dL), n (%) 5 (18.5)
COPD, n (%) 7 (25.9)
Chronic obstructive arterial disease, n (%) 2 (7.4)
Previous CABG, n (%) 2 (7.4)
Previous PCI, n (%) 11 (40.7)
Untreated obstructive CAD, n (%) 2 (7.4)
Previous MI, n (%) 7 (25.9)
Previous Stroke, n (%) 3 (11.1)
Class NYHA III-IV pre-TAVI, n (%) 27 (100)
Class NYHA III-IV post-TAVI, n (%) 0 (0)
Implanted valve
Medtronic CoreValve26 mm, n (%) 11 (40.7)
Medtronic CoreValve 29 mm, n (%) 10 (37.1)
Edwards SAPIEN 23 mm, n (%) 1 (3.7)
Edwards SAPIEN 26 mm, n (%) 5 (18.5)
BMI body mass index; CABG coronary artery by-pass graft; CAD coronary artery
disease; COPD chronic obstructive pulmonary disease; MI myocardial infarction;
PCI percutaneous coronary intervention.
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flip angle 25°, field of view 320 mm, slices thickness
10 mm, acquired in the left ventricular short axis over 2
RR intervals and no interslice gap. LGE was evaluated
by visual assessment in short-axis slices and further
characterized by spatial location, pattern, and LGE
quantification (1–25%, 25–50%, 50–75%, >75%) [20].
Statistical analysis
Quantitative data were presented as mean ± standard
deviations and were compared using the Student t paired
test. Univariate and multivariate correlates of left ven-
tricular reverse remodeling were analyzed by logistic
regression. To explore their significance as baseline
predictors, LVMi (< or ≥ 89 g/m2) and LVEF (< or ≥ 55%)
were dichotomyzed as previously described [19]. A
two-sided p value of < 0.05 was considered to indicate
statistical significance. All data were processed using
the Statistical Package for Social Sciences, version 15
(SPSS, Chicago, IL, USA).
Results
The study cohort had a mean age of 80.7±5.2 years.
Detailed reasons for TAVI referral were the following: 16
(59.3%) patients had a proibitive Logistic EuroSCORE, 1
(3.7%) patient had a porcelain aorta, 3 patients (11.1%)
had received thoracic radiation therapy for lung cancer, 1
(3.7%) had a severe form of diabetic lipodystrophy, 1
patient (3.7%) had cirrhosis and 5 patients (18.5%) refused
surgery. All patients were in New York Heart Association
class III-IV and 37% of them were previously hospitalized
for congestive heart failure (Table 1). The Medtronic
CoreValve and Edwards SAPIEN prostheses were used in
21 (77.8%) and 6 (22.2%) of cases, respectively (Table 1,
Figure 2). All patients showed an improvement in
symptoms at six-month follow-up (all were in New York
Heart Association class I-II).
CMR outcomes
All patients well tolerated CMR and no clinical adverse
event was recorded during the examination both at
baseline and at 6 months. The images quality was
diagnostic in 100% of examinations. The mass/vol-
ume ratio decreased significantly from baseline to
follow-up (P=0.001) (Table 2, Figure 3). Figure 4 dis-
plays changes in CMR endpoints from baseline to
follow up. LVMi decreased from 84.5±25.2 g/m2 to
69.4±18.4 g/m2 (P<0.001). Conversely, LVEDVi, SV
and LVEF did not change significantly (Table 2,
Figure 4). After entering in a multivariable model all
potential baseline confounding factors with p<0.20 at
univariate analysis, no significant predictors of left
ventricular reverse remodeling was identified.Because myocardial fibrosis may significantly impact
clinical outcomes [21], we repeated the analysis by
excluding patients with fibrosis of ischemic or non
ischemic nature (N=10) and found a consistent evidence
of significant LVMi reduction (83.9 ± 28.9 g/m2vs 69.5±
22.3 g/m2, P <0.001), with no significant changes for other
parameters (Table 3).
Gadolinium was not administered to 3 patients due to
severe renal failure (creatinine clearance <30 ml/min).
At baseline, evidence of LGE was present in 10 (41.6%)
of 24 cases. Causes for LGE were ischemic in 8 cases, and
non-ischemic in 2 cases (Figure 5). At follow up, there
Figure 2 CMR left ventricular outflow tract cine view after TAVI. Panel A. Core Valve bioprosthesis; Panel B. Edwards SAPIEN
valve bioprosthesis.
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although one patient did have a pre-procedural myocardial
infarction with new LGE at follow up.
Discussion
Although limited by the small sample size, our study
enables a deeper understanding of left ventricular reverse
remodeling occurring after TAVI in a complex clinical
cohort, by means of a reliable and accurate technique
as CMR. In particular, at six months, we observed a
statistically significant reduction of LVMi.
Regression of myocardial hypertrophy due to the
decrease of ventricular afterload after surgical aortic valve
replacement is a well-recognized phenomenon [5,22,23].
In particular, left ventricular mass decreases mainly withinFigure 3 Changes in CMR mass/volume ratio from baseline to follow-
0.82±0.18 at six months follow-up (P=0.001).the first six months after surgical valve replacement.
This observation has been also proven in studies based
on CMR. In a CMR study of 24 patients, Biederman
et al. [24] demonstrated that following surgical valve
replacement, left ventricular mass markedly decreased
at six months (157 ± 42 to 134 ± 32 g/m2, p < 0.005)
and continued to further trend downward at 4 years
(127 ± 32 g/m2; p =NS). Lamb et al. [25] showed that,
early after surgical valve replacement, patients with aortic
valve stenosis show a decrease in both LVMi, LVMi/
LVEDVi ratio and improvement in diastolic filling.
Studies based on echocardiography seem to confirm that
after TAVI the left ventricle undergoes a similar reverse
remodeling process [26-30]. In a study by Giannini
et al. comparing patients who underwent TAVI with theup. The mass/volume ratio decreased from 0.99±0.2 at baseline to
Table 2 CMR characteristics in the study population
Baseline Sixmonths P
N = 27 N = 27
LVEF (%) 61.5±14.5 65.1±7.2 0.08
LVEDV (ml) 151.4±50.1 151.7±38.9 0.97
LVEDVi (ml/m2) 87.2±30.14 86.4±22.3 0.84
LVESV (ml) 61.1±44.6 53.4±19.2 0.16
LVESVi (ml/m2) 35.29±24.7 30.5±11.5 0.15
LVM (g) 148.2±44.6 122.5±34.8 <0.001
LVMi (g/m2) 84.5±25.2 69.4±18.4 <0.001
Stroke volume (ml) 89.2±22 94.7±26.5 0.25
CardiacOutput (L/min) 5.9±1.4 5.9±1.3 0.98
Mass/Volume ratio 0.99±2 0.82±0.18 0.001
CMR cardiovascular magnetic resonance; LVEDVi indexed left ventricular end
diastolic volume; LVESVi indexed left ventricular end systolic volume; LVMi
indexed left ventricular mass; LVEDV left ventricular end diastolic volume;
LVEF left ventricular ejection fraction; LVM left ventricular mass; LVESV left
ventricular end systolic volume.
Figure 4 Changes in CMR endpoints from baseline to follow up. LVED
94.7 ml ±26.5; p = 0.25) and LVEF (61.5±14.5% vs 65.1±7.2%, p = 0.08), did
25.2 g/m2 at baseline to 69.4±18.4 g/m2 at six months follow-up (p < 0.001
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surgical aortic replacement, left ventricular reverse
remodeling was found in all patients in the absence of
prosthesis-patient mismatch [29]. Tzikas et al. found a
significant regression in left ventricular masses in 63
consecutive patients one year after TAVI. However,
regression was incomplete and was not accompanied
by an improvement in left ventricular diastolic function
[30]. However, it is important to underscore that transtho-
racic echocardiography has several limitations for the
assessment of left ventricular volumes and LVEF, while
CMR is currently considered the gold-standard for their
assessment, especially in case of heart failure, myocardial
infarction, cardiomyopathy, poor acoustic window or
discrepancies between different methodologies [16]. In
fact, the accuracy of left ventricular volumes and LVEF
with two-dimensional echocardiography is limited by
image position, geometric assumptions, and boundary
tracing errors [31]. To date, few studies have beenVi (87.2±30.1 ml /m2vs 86.4±22.3 ml/m2; p = 0.84), SV (89.2±22 ml vs
not change significantly (Panel A, B, C). LVMi decreased from 84.5±
) (Panel D).
Table 3 CMR characteristics of patients without fibrosis at
baseline
Baseline Sixmonths P
N= 17 N= 17
LVEF (%) 63.9±14.6 67.6±76.5 0.15
LVEDV (ml) 152.7±57.5 154.7±44.2 0.82
LVEDVi (ml/m2) 87.1±35 87.0±25.2 0.99
LVESV (ml) 60±48.8 51.1±22.7 0.27
LVESVi (ml/m2) 34.5±29 28.9±13.4 0.25
LVM (g) 148.0±50.4 124.7±41.8 0.000
LVMi (g/m2) 83.9±28.9 69.5±22.3 0.000
Stroke volume (ml) 90.9±20 98.5±28 0.57
CardiacOutput (L/min) 5.9±1.3 6.2±1.3 0.98
CMR cardiovascular magnetic resonance; LVEDVi indexed left ventricular end
diastolic volume; LVESVi indexed left ventricular end systolic volume; LVMi
indexed left ventricular mass; LVEDV left ventricular end diastolic volume; LVEF
left ventricular ejection fraction; LVM left ventricular mass; LVESV left
ventricular end systolic volume.
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after TAVI [32,33]. Indeed, CMR is a noninvasive technique
that allows for accurate measurement of left ventricular
mass and volumes with high reproducibility without the
use of geometric assumptions, thereby providing potentially
more accurate information [34].
The significant reduction of the left ventricular mass
observed in our study was not accompanied by a corre-
sponding significant increase in LVEF and SV. Several
studies demonstrated improved LVEF after surgical aortic
valve replacement, particularly in patients with low
preoperative ejection fraction [35]. However, in patients
with normal preoperative LVEF, results were variable. In
particular, it has been suggested that the improvement in
left ventricular function is more pronounced in patientsFigure 5 Different patterns of LGE in TAVI patients. Focal mid-wall fibr
myocardial necrosis at basal segment of the inferior wall (Panel B).with LVEF < 50% [35]. Parameters that could influence
the left ventricular reverse remodeling process include age
[36], female sex [37], size of the prosthesis [38], presence
of fibrosis [39] and myocardial perfusion reserve [40]. In
addition, we have not observed the significant change in
left ventricular volume shown in studies of the surgical
aortic valve replacement [24,25,39]. This may suggest a
different process of reverse remodeling between TAVI and
SAVR, but the lack of a comparative control arm in
our study does not allow drawing firm conclusions in
this regards.
We did not collect CMR data regarding post-TAVI
aortic regurgitation that could have influenced left ven-
tricular remodeling. However, based on trans-thoracic
echocardiography, no patient had a residual severe aortic
insufficiency, while a mild to moderate insufficiency
was present in 4 patients, a mild insufficiency in 7 and no
hemodynamically significant regurgitation in the remaining
population. Moreover, another major limitation of this
study is the lack of information on diastolic dysfunction,
flow, and changes in gradients and aortic valve areas pre
and post TAVI. Finally, our study demonstrated the absence
of periprocedural myocardial infarction potentially caused
by the deployment of the prosthesis and possible calcium
embolization.
Conclusions
This CMR study explored the mid-term hemodynamic
effects of TAVI. Our results expands on previous findings
from echocardiography studies by means of a more
precise and reliable imaging technique. A significant left
ventricular reverse remodeling was shown at 6 months
from TAVI. The implication of this finding remains
unclear and should be explored in large dedicated studies
with clinical endpoints.osis at mid segment of the inferior wall (Panel A). Focal transmural
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